Study of Sorafenib/Cetuximab in Head and Neck Cancer

NCT00815295 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

31

Enrollment

OTHER

Sponsor class

Conditions

Squamous Cell Cancer

Interventions

DRUG: Sorafenib
DRUG: Cetuximab

Sponsor

Duke University

Collaborators

[object Object]